{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:01:32Z","timestamp":1772755292295,"version":"3.50.1"},"reference-count":88,"publisher":"Impact Journals, LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,1,24]]},"DOI":"10.18632\/oncotarget.12786","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T23:50:39Z","timestamp":1477007439000},"page":"7201-7207","source":"Crossref","is-referenced-by-count":26,"title":["Bruton tyrosine kinase inhibitor ONO\/GS-4059: from bench to bedside"],"prefix":"10.18632","volume":"8","author":[{"given":"Jingjing","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,10,20]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Bruton. Agammaglobulinemia. Pediatrics. 1952; 9(6):722\u2013728.","DOI":"10.1542\/peds.9.6.722"},{"issue":"6","key":"2","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/jmg.30.6.452","article-title":"Isolation of the defective gene in X linked agammaglobulinaemia","volume":"30","author":"Vetrie","year":"1993","journal-title":"J Med Genet"},{"key":"3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1155\/2001\/28962","article-title":"Role of Bruton's tyrosine kinase in B cell development","volume":"8","author":"Hendriks","year":"2001","journal-title":"Dev Immunol"},{"issue":"12","key":"4","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/humu.20410","article-title":"BTKbase: the mutation database for X-linked agammaglobulinemia","volume":"27","author":"Vihinen","year":"2006","journal-title":"Hum Mutat"},{"issue":"2","key":"5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia","volume":"72","author":"Quan","year":"1993","journal-title":"Cell"},{"issue":"6409","key":"6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","volume":"361","author":"Bobrow","year":"1993","journal-title":"Nature"},{"key":"7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2162-3619-3-4","article-title":"Ibrutinib for B cell malignancies","volume":"3","author":"Liu","year":"2014","journal-title":"Exp Hematol Oncol"},{"issue":"9","key":"8","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1182\/blood-2011-12-396853","article-title":"Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma","volume":"120","author":"Carrasco","year":"2012","journal-title":"Blood"},{"issue":"3","key":"9","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/0008-5472.CAN-14-2362","article-title":"Tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma","volume":"75","author":"Bruton.","year":"2015","journal-title":"Cancer Res"},{"issue":"23","key":"10","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Byrd","year":"2011","journal-title":"Blood"},{"issue":"8","key":"11","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2006-01-011817","article-title":"Bruton tyrosine kinase is essential for botrocetin\/VWF-induced signaling and GPIb-dependent thrombus formation in vivo","volume":"108","author":"Gartner","year":"2006","journal-title":"Blood"},{"issue":"1","key":"12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Liu","year":"2012","journal-title":"Exp Hematol Oncol"},{"issue":"26","key":"13","doi-asserted-by":"crossref","first-page":"18201","DOI":"10.1074\/jbc.M603090200","article-title":"Regulation of Bruton tyrosine kinase by the peptidylprolyl isomerase Pin1","volume":"281","author":"Smith","year":"2006","journal-title":"J Biol Chem"},{"key":"14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-014-0070-8","article-title":"Strategies for modern biomarker and drug development in oncology","volume":"7","author":"Yap","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"1","key":"15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-015-0224-3","article-title":"ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development","volume":"8","author":"Liu","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"1","key":"16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-018-0093-x","article-title":"Selective inhibitors of nuclear export (SINE) in hematological malignancies","volume":"4","author":"Liu","year":"2015","journal-title":"Exp Hematol Oncol"},{"issue":"12","key":"17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Dohner","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-015-0122-8","article-title":"Novel ALK inhibitors in clinical use and development","volume":"8","author":"Liu","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"1","key":"19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","article-title":"Selective inhibitors of nuclear export (SINE)- a novel class of anti-cancer agents","volume":"7","author":"Liu","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"23","key":"20","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood.V126.23.832.832","article-title":"The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed\/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial","volume":"126","author":"Roberts","year":"2015","journal-title":"Blood"},{"key":"21","doi-asserted-by":"publisher","first-page":"38225","DOI":"10.18632\/oncotarget.5425","article-title":"Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1756-8722-7-33","article-title":"A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies","volume":"7","author":"Back","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"12","key":"23","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMe1400599","article-title":"Movement toward optimization of CLL therapy","volume":"370","author":"Barrientos","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"24","first-page":"728","article-title":"A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells","volume":"6","author":"Zhukovsky","year":"2014","journal-title":"mAbs"},{"issue":"3","key":"25","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/19420862.2015.1029216","article-title":"A tetravalent bispecific TandAb (CD19\/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells","volume":"7","author":"Zhukovsky","year":"2015","journal-title":"mAbs"},{"issue":"1","key":"26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-014-0058-4","article-title":"New antibody approaches to lymphoma therapy","volume":"7","author":"Barta","year":"2014","journal-title":"J Hematol Oncol"},{"key":"27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-015-0188-3","article-title":"AFM13: a first-in-class tetravalent bispecific anti-CD30\/CD16A antibody for NK cell-mediated immunotherapy","volume":"8","author":"Liu","year":"2015","journal-title":"J Hematol Oncol"},{"key":"28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-015-0195-4","article-title":"Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19\/CD3 for refractory acute lymphoid leukemia","volume":"8","author":"Liu","year":"2015","journal-title":"J Hematol Oncol"},{"key":"29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12943-015-0474-2","article-title":"Novel drug targets for personalized precision medicine in relapsed\/refractory diffuse large B-cell lymphoma: a comprehensive review","volume":"14","author":"Hassa","year":"2015","journal-title":"Molecular Cancer"},{"key":"30","doi-asserted-by":"publisher","first-page":"43881","DOI":"10.18632\/oncotarget.6316","article-title":"Cerdulatinib, a novel dual SYK\/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"31","doi-asserted-by":"publisher","first-page":"35202","DOI":"10.18632\/oncotarget.6051","article-title":"MCL-1-independent mechanisms of synergy between dual PI3K\/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma","volume":"6","author":"Fruman","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2162-3619-3-4","article-title":"Ibrutinib for B cell malignancies","volume":"3","author":"Liu","year":"2014","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","article-title":"Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor","volume":"9","author":"Liu","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"4","key":"34","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/bjh.12573","article-title":"Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas","volume":"163","author":"Advani","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"35","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Fowler","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Woyach","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton tyrosine kinase (BTK) and its role in B-cell malignancy","volume":"31","author":"Elias","year":"2012","journal-title":"Int Rev Immunol"},{"issue":"1","key":"38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11899-013-0188-8","article-title":"Bruton's tyrosine kinase (BTK) inhibitors in clinical trials","volume":"9","author":"Burger","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"11","key":"39","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.3109\/10428194.2013.777837","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)","volume":"54","author":"Buggy","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"40","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Quach","year":"2015","journal-title":"N Engl J Med"},{"issue":"29","key":"41","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Buggy","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase","volume":"2","author":"Palmer","year":"2007","journal-title":"ChemMedChem"},{"key":"43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-015-0165-x","article-title":"Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia","volume":"8","author":"Rai","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"1","key":"44","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Chang","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"45","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMc1506192","article-title":"MYD88 Mutations and Response to Ibrutinib in Waldenstrom's Macroglobulinemia","volume":"373","author":"Hunter","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"46","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Jedrzejczak","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"47","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10875-014-0046-z","article-title":"The effects of Bruton tyrosine kinase inhibition on chemotaxis and superoxide generation in human neutrophils","volume":"34","author":"Levy","year":"2014","journal-title":"J Clin Immunol"},{"issue":"3","key":"48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Pocock","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/PPO.0000000000000170","article-title":"Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders","volume":"22","author":"Davids","year":"2016","journal-title":"Cancer J"},{"issue":"15","key":"50","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Kanan","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"51","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"O\u2019Brien","year":"2015","journal-title":"Blood"},{"issue":"17","key":"52","doi-asserted-by":"crossref","first-page":"8152","DOI":"10.1073\/pnas.91.17.8152","article-title":"Binding of Bruton's tyrosine kinase to Fyn, Lyn, or Hck through a Src homology 3 domain-mediated interaction","volume":"91","author":"Baltimore","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"53","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1001\/jamaoncol.2015.0457","article-title":"Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias","volume":"1","author":"Jones","year":"2015","journal-title":"JAMA Oncol"},{"issue":"26","key":"54","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"Payrastre","year":"2014","journal-title":"Blood"},{"issue":"3","key":"55","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1182\/blood.V85.3.627.bloodjournal853627","article-title":"Association and activation of Btk and Tec tyrosine kinases by gp130, a signal transducer of the interleukin-6 family of cytokines","volume":"85","author":"Hirano","year":"1995","journal-title":"Blood"},{"issue":"25","key":"56","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"Tam","year":"2014","journal-title":"Blood"},{"issue":"4","key":"57","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nri1591","article-title":"TEC-family kinases: regulators of T-helper-cell differentiation","volume":"5","author":"Readinger","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"58","doi-asserted-by":"crossref","first-page":"27","DOI":"10.21037\/sci.2016.06.08","article-title":"Successful treatment of ibrutinib-associated central nervous system hemorrhage with platelet transfusion support","volume":"3","author":"Liu","year":"2016","journal-title":"Stem Cell Investigation"},{"issue":"24","key":"59","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Lozanski","year":"2014","journal-title":"N Engl J Med"},{"issue":"24","key":"60","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Wang","year":"2014","journal-title":"N Engl J Med"},{"key":"61","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","article-title":"Second-generation inhibitors of Bruton tyrosine kinase","volume":"9","author":"Liu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"62","doi-asserted-by":"publisher","first-page":"68833","DOI":"10.18632\/oncotarget.11932","article-title":"Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"63","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Sharpe","year":"2016","journal-title":"Blood"},{"issue":"8 Supplement","key":"64","first-page":"857","article-title":"Abstract 857: Development of a Bruton's tyrosine kinase (Btk) inhibitor - ONO-WG-307, a potential treatment for B-cell malignancies","volume":"72","author":"Kawabata","year":"2012","journal-title":"Cancer Research"},{"issue":"8 Supplement","key":"65","first-page":"2021","article-title":"Abstract 2021: ONO-WG-307, a novel, potent and selective inhibitor of Bruton's tyrosine kinase (Btk), results in sustained inhibition of the ERK, AKT and PKD signaling pathways","volume":"72","author":"Kawabata","year":"2012","journal-title":"Cancer Research"},{"issue":"8 Supplement","key":"66","first-page":"2452","article-title":"Abstract 2452: ONO-4059, a novel oral Bruton's tyrosine kinase (Btk) inhibitor that demonstrates potent pharmacodynamic activity through Phosphorylated Btk (P-Btk) inhibition, in addition to effective anti-tumour activity in a TMD-8 (DLBCL) xenograft model","volume":"73","author":"Birkett","year":"2013","journal-title":"Cancer Research"},{"issue":"23","key":"67","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1182\/blood.V126.23.3697.3697","article-title":"Combination of Idelalisib and ONO\/GS-4059 in Lymphoma Cell Lines Sensitive and Resistant to BTK Inhibitors","volume":"126","author":"Queva","year":"2015","journal-title":"Blood"},{"issue":"23","key":"68","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood.V126.23.1749.1749","article-title":"Combination Effects of B Cell Receptor Pathway Inhibitors (Entospletinib, ONO\/GS-4059, and Idelalisib) and a BCL-2 Inhibitor in Primary CLL Cells","volume":"126","author":"Di Paolo","year":"2015","journal-title":"Blood"},{"key":"69","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12943-015-0388-z","article-title":"Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms","volume":"14","author":"Kapur","year":"2015","journal-title":"Molecular Cancer"},{"issue":"23","key":"70","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1182\/blood.V126.23.3707.3707","article-title":"Up-Regulation of the PI3K Signaling Pathway Mediates Resistance to Idelalisib","volume":"126","author":"Tannheimer","year":"2015","journal-title":"Blood"},{"key":"71","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1756-8722-6-88","article-title":"Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics","volume":"6","author":"Liu","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"15","key":"72","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood-2014-08-595934","article-title":"An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia","volume":"125","author":"Yasenchak","year":"2015","journal-title":"Blood"},{"key":"73","doi-asserted-by":"crossref","first-page":"8553","DOI":"10.1200\/jco.2014.32.15_suppl.8553","article-title":"Abstract 8553: The Bruton's tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL","volume":"32","author":"Rule","year":"2014","journal-title":"J Clin Oncol"},{"issue":"21","key":"74","article-title":"Abstract 4397: A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed\/Refractory B-Cell Lymphoma","volume":"122","author":"Salles","year":"2013","journal-title":"Blood"},{"issue":"21","key":"75","article-title":"Abstract 676: A Phase I Study Of The Oral Btk Inhibitor ONO-4059","volume":"122","author":"Rule","year":"2013","journal-title":"In Patients With Relapsed\/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL). Blood"},{"issue":"1","key":"76","first-page":"57","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Schiller","year":"2014","journal-title":"Lancet Oncol"},{"issue":"26","key":"77","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Burmeister","year":"2012","journal-title":"Blood"},{"key":"78","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-015-0227-0","article-title":"Bispecific antibodies and their applications","volume":"8","author":"Li","year":"2015","journal-title":"J Hematol Oncol"},{"key":"79","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40364-016-0061-8","article-title":"Treatment with rituximab and brentuximab vedotin in a patient of common variable immune deficiency-associated classic Hodgkin lymphoma","volume":"4","author":"Zheng","year":"2016","journal-title":"Biomarker Research"},{"key":"80","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Forero-Torres","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"26","key":"81","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Chen","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"82","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Allison","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"83","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13045-015-0219-0","article-title":"Nivolumab plus ipilimumab in the treatment of advanced melanoma","volume":"8","author":"Daud","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"5","key":"84","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood-2014-11-612903","article-title":"Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein","volume":"126","author":"Sorensen","year":"2015","journal-title":"Blood"},{"issue":"16","key":"85","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Levine","year":"2014","journal-title":"N Engl J Med"},{"key":"86","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coi.2016.02.006","article-title":"Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection","volume":"40","author":"Maus","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"87","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1476-4598-13-219","article-title":"Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects","volume":"13","author":"Wang","year":"2014","journal-title":"Mol Cancer"},{"key":"88","doi-asserted-by":"publisher","first-page":"42232","DOI":"10.18632\/oncotarget.6273","article-title":"Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma","volume":"6","author":"Krappmann","year":"2015","journal-title":"Oncotarget"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T22:02:55Z","timestamp":1657490575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,20]]},"references-count":88,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,1,24]]}},"alternative-id":["12786","27776353"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.12786","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,20]]}}}